What are the findings from the network analysis regarding antihypertensive treatment algorithms in CKD?
The results of the network analysis were not sub-divided by diabetes or albuminuria status, so any antihypertensive treatment algorithm in CKD beyond monotherapy depends on expert opinion, pathophysiologic or pharmacodynamic considerations, extrapolation from findings in primary hypertension in the absence of CKD, and small studies in CKD with surrogate outcomes, namely change in BP over the short term or meta-analyses of underpowered studies.